Skip to main content

Table 2 Correlation between c-maf expression and treatment response of multiple myeloma patients

From: Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma

  All patients (n = 116) C-maf-positive (n = 36) C-maf-negative (n = 80) p value
Therapy, n (%)
 Bor 70 (60.3) 22 (61.1) 48 (60.0)  
 Non-bor 46 (39.7) 14 (38.9) 32 (40.0) 0.910
Courses, n (%)
 <3 44 (37.9) 11 (30.6) 33 (41.3)  
 ≥3 72 (62.1) 25 (69.4) 47 (58.7) 0.272
Response (ORR), n (%)
 <PR 50 (46.9) 12 (43.6) 38 (48.3)  
 ≥PR 66 (53.1) 24 (56.4) 42 (51.7) 0.154
Response (VGPR), n (%)
 <VGPR 63 (54.3) 22 (61.1) 41 (51.3)  
 ≥VGPR 53 (45.7) 14 (38.9) 39 (48.7) 0.324
Courses ≥3 N = 69 N = 24 N = 45  
Response (ORR), n (%)
 <PR 7 (10.1) 3 (12.5) 4 (8.9)  
 ≥PR 62 (89.9) 21 (87.5) 41 (91.1) 0.641
Response (VGPR), n (%)
 <VGPR 20 (29.0) 10 (41.7) 10 (22.2)  
 ≥VGPR 49 (71.0) 14 (58.3) 35 (77.8) 0.090
Bortezomib N = 48 N = 16 N = 32  
Response (ORR), n (%)
 <PR 4 (8.3) 1 (6.3) 3 (9.4)  
 ≥PR 44 (91.7) 15 (93.7) 29 (90.6) 0.712
Response (VGPR), n (%)
 <VGPR 10 (20.8) 3 (18.8) 7 (21.9)  
 ≥VGPR 38 (79.2) 13 (81.2) 25 (78.1) 0.800
Non-bortezomib N = 21 N = 8 N = 13  
Response (ORR), n (%)
 <PR 3 (14.3) 2 (25.0) 1 (7.7)  
 ≥PR 18 (85.7) 6 (75.0) 12 (92.3) 0.278
Response (ORR), n (%)
 <VGPR 10 (47.6) 7 (87.5) 3 (23.1)  
 ≥VGPR 11 (52.4) 1 (12.5) 10 (76.9) 0.003
  1. Bor bortezomib, ORR overall response rate, VGPR very good partial response